NEXTURNBIOSCIENCE Co., Ltd.

KOSDAQ:A089140 Stock Report

Market Cap: ₩33.2b

NEXTURNBIOSCIENCE Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Young-Hwa Jung

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

NEXTURNBIOSCIENCE Co., Ltd.'s (KOSDAQ:089140) 38% Share Price Plunge Could Signal Some Risk

Dec 02
NEXTURNBIOSCIENCE Co., Ltd.'s (KOSDAQ:089140) 38% Share Price Plunge Could Signal Some Risk

NEXTURNBIOSCIENCE Co., Ltd.'s (KOSDAQ:089140) Shares Climb 33% But Its Business Is Yet to Catch Up

Oct 17
NEXTURNBIOSCIENCE Co., Ltd.'s (KOSDAQ:089140) Shares Climb 33% But Its Business Is Yet to Catch Up

NEXTURNBIOSCIENCE Co., Ltd.'s (KOSDAQ:089140) 33% Price Boost Is Out Of Tune With Revenues

Oct 17
NEXTURNBIOSCIENCE Co., Ltd.'s (KOSDAQ:089140) 33% Price Boost Is Out Of Tune With Revenues

Does NEXTURNBIOSCIENCE (KOSDAQ:089140) Have A Healthy Balance Sheet?

Aug 13
Does NEXTURNBIOSCIENCE (KOSDAQ:089140) Have A Healthy Balance Sheet?

NEXTURNBIOSCIENCE's (KOSDAQ:089140) Attractive Earnings Are Not All Good News For Shareholders

Mar 28
NEXTURNBIOSCIENCE's (KOSDAQ:089140) Attractive Earnings Are Not All Good News For Shareholders

Shareholders Of NexturnLtd (KOSDAQ:089140) Must Be Happy With Their 119% Total Return

Jan 25
Shareholders Of NexturnLtd (KOSDAQ:089140) Must Be Happy With Their 119% Total Return

CEO

Young-Hwa Jung (65 yo)

no data

Tenure

Mr. Jung Young-Hwa serves as the Chief Executive Officer of NexturnBioscience Co., Ltd (formerly known as Nexturn Co.,Ltd.)


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 08:33
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NEXTURNBIOSCIENCE Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
KYUNG SEOB KIMShinhan Investment Corp.
Sun Hwa LeeSK Securities Co., Ltd.